Tiziana Life Sciences Ltd

NASDAQ:TLSA

Biotechnology

Healthcare
$0.81 +2.78%

+$0.03 today

Market cap
$103.50M
Beta
0.42
P/E (TTM)
-4.0
EPS (TTM)
-$0.19
52W Low $1.04High $2.60

Volume 1.28M

Average 0.21M

TLSA Net Income

Bottom-line profit after all expenses, interest, and taxes.

Tiziana Life Sciences LtdNASDAQ: TLSA

Net Income · Q4 FY2025 · quarter ended Dec 2025

Net income remains negative

Q4 FY2025 net income was -$12.8M, compared with -$7.21M a year earlier.

Context

  • Net income grew in size in 2 of the last 3 fiscal years.

What to watch

Whether net income reaches the consensus estimate of -$9.45M (+48.7%) for the fiscal year ending Dec 2026, a step up from the -55.4% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterDec 2025
-$12.8M— QoQ
Last fiscal yearDec 2025
-$18.43M-55.4% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-77.5%——
1 year-55.4%+48.7%+104.1 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the income statement

Latest · FY2025
(18.43M) USD
Year-over-year change
-55.4%
Reported Analyst consensus estimate

Net Income vs competitors

How TLSA compares with its peers on the latest reported figures

  • TLSA's FY2025 net income of -$18.43M is the 3rd highest of the 9 companies compared; the peer median is -$52.67M.
  • Its year-over-year change of -55.4% is the 7th highest of 9, against a peer median of -24.7%.
TLSA Competitors Peer median
Net Income for TLSA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
OKYOOKYO Pharma LimitedFY2025-$4.71M +72.0%——
EXOZeXoZymes, Inc.LTM Mar 2026-$9.67M -44.2%——
TLSATiziana Life Sciences LtdFY2025-$18.43M -55.4%——
COYACoya Therapeutics, Inc.LTM Mar 2026-$21.13M -23.3%—266.1%
IMMXImmix Biopharma, Inc.LTM Mar 2026-$34.98M -67.4%——
MGNXMacroGenics, Inc.LTM Mar 2026-$70.36M -26.1%—44.8%
PLRXPliant Therapeutics, Inc.LTM Mar 2026-$113.22M +48.4%——
WHWKWhitehawk Therapeutics IncLTM Mar 2026-$115.81M -519.4%——
ZNTLZentalis Pharmaceuticals, Inc.LTM Mar 2026-$124.13M +44.6%——
Peer median (excluding TLSA) -$52.67M-24.7%—155.4%

Competitors are the stored peer set for TLSA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue0000234K
Gross Profit0000(234K)
Gross Margin—————
Research & Development17.82M15.92M10.25M5.23M10.28M
Selling, General & Admin1.15M4.76M8.26M10.28M10.77M
Operating Expenses36.93M17.93M22.73M15.79M21.05M
Depreciation & Amortization190.2K62.68K121.34K124K234K
EBITDA(35.53M)(18.85M)(21.66M)(16.62M)(21.05M)
EBITDA Margin—————
Operating Income(36.93M)(17.93M)(22.73M)(15.79M)(21.28M)
Operating Margin—————
Interest Income001.46M814K19K
Interest Expense237.41K8.6K12.64K6K18K
Other Income / Expenses967.18K(996.78K)937.89K(952K)2.85M
Income Before Tax(35.96M)(18.92M)(21.79M)(16.75M)(18.43M)
Pre-Tax Margin—————
Income Tax Expense(4.37M)0567.54K(4.88M)0
Net Income(31.59M)(18.92M)(22.36M)(11.86M)(18.43M)
Net Margin—————
EPS (Basic)(0.64)(0.36)(0.42)(0.22)(0.32)
EPS (Diluted)(0.64)(0.36)(0.42)(0.22)(0.32)
Weighted Avg Shares48.97M50.76M50.76M53.34M59.14M
Weighted Avg Shares (Diluted)48.97M50.76M50.76M53.34M59.14M

Tiziana Life Sciences Ltd

NASDAQ:TLSA

Intrinsic Alpha fair value

Locked

Current Price

$0.81

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.